PURPOSE OF REVIEW: Solid organ xenotransplantation could be the future of transplantation, but improved outcomes are required in experimental models before clinical trials are justified. This review summarizes recent advances in solid organ xenotransplantation using organs from α1,3-galactosyltransferase gene-knockout (GTKO) pigs (with or without other genetic modifications) and novel therapeutic approaches. RECENT FINDINGS: Work on the development of genetically engineered pigs has been considerable during the past few years, with many research institutes reporting the outcomes of research. Multiple gene modifications on a GTKO background have been reported, and the results of transplantation using organs from these pigs have been published. Progress, however, has been variable, and several obstacles, for example, coagulation dysregulation, have been identified. Heterotopic pig heart xenotransplantation has been associated with graft survival up to 8 months, but kidney graft survival has not improved significantly. SUMMARY: The availability of GTKO pigs with additional genetic modifications aimed toward expression of multiple complement-regulatory proteins and/or human thromboregulatory genes, combined with novel immunosuppressive regimens, for example, the inclusion of B cell-depleting agents, should improve pig organ survival in the near future.
PURPOSE OF REVIEW: Solid organ xenotransplantation could be the future of transplantation, but improved outcomes are required in experimental models before clinical trials are justified. This review summarizes recent advances in solid organ xenotransplantation using organs from α1,3-galactosyltransferase gene-knockout (GTKO) pigs (with or without other genetic modifications) and novel therapeutic approaches. RECENT FINDINGS: Work on the development of genetically engineered pigs has been considerable during the past few years, with many research institutes reporting the outcomes of research. Multiple gene modifications on a GTKO background have been reported, and the results of transplantation using organs from these pigs have been published. Progress, however, has been variable, and several obstacles, for example, coagulation dysregulation, have been identified. Heterotopic pig heart xenotransplantation has been associated with graft survival up to 8 months, but kidney graft survival has not improved significantly. SUMMARY: The availability of GTKO pigs with additional genetic modifications aimed toward expression of multiple complement-regulatory proteins and/or human thromboregulatory genes, combined with novel immunosuppressive regimens, for example, the inclusion of B cell-depleting agents, should improve pig organ survival in the near future.
Authors: A D Griesemer; A Hirakata; A Shimizu; S Moran; A Tena; H Iwaki; Y Ishikawa; P Schule; J S Arn; S C Robson; J A Fishman; M Sykes; D H Sachs; K Yamada Journal: Am J Transplant Date: 2009-10-21 Impact factor: 8.086
Authors: Yannick D Muller; Déla Golshayan; Driss Ehirchiou; Thomas Wekerle; Jörg D Seebach; Leo H Bühler Journal: Xenotransplantation Date: 2009 May-Jun Impact factor: 3.907
Authors: Jagdeece Ramsoondar; Todd Vaught; Suyapa Ball; Michael Mendicino; Jeff Monahan; Peter Jobst; Amy Vance; Jane Duncan; Kevin Wells; David Ayares Journal: Xenotransplantation Date: 2009 May-Jun Impact factor: 3.907
Authors: C Knosalla; K Yazawa; A Behdad; N Bodyak; H Shang; L Bühler; S Houser; B Gollackner; A Griesemer; I Schmitt-Knosalla; H-J Schuurman; M Awwad; D H Sachs; D K C Cooper; K Yamada; A Usheva; S C Robson Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: Elisabeth H Weiss; Benjamin G Lilienfeld; Sigrid Müller; Elfriede Müller; Nadja Herbach; Barbara Kessler; Rüdiger Wanke; Reinhard Schwinzer; Jörg D Seebach; Eckhard Wolf; Gottfried Brem Journal: Transplantation Date: 2009-01-15 Impact factor: 4.939
Authors: Carol J Phelps; Suyapa F Ball; Todd D Vaught; Amy M Vance; Michael Mendicino; Jeffrey A Monahan; Anneke H Walters; Kevin D Wells; Amy S Dandro; Jagdeece J Ramsoondar; David K C Cooper; David L Ayares Journal: Xenotransplantation Date: 2009 Nov-Dec Impact factor: 3.907
Authors: Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso Journal: Xenotransplantation Date: 2011 Nov-Dec Impact factor: 3.907
Authors: Vikas Satyananda; Hidetaka Hara; Mohamed B Ezzelarab; Carol Phelps; David Ayares; David K C Cooper Journal: Transplantation Date: 2013-12-15 Impact factor: 4.939
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Robert F Hoyt; Marvin L Thomas; David Ayares; Keith A Horvath Journal: J Thorac Cardiovasc Surg Date: 2014-06-06 Impact factor: 5.209
Authors: Hidetaka Hara; William Witt; Tanner Crossley; Cassandra Long; Kumiko Isse; Liming Fan; Carol J Phelps; David Ayares; David K C Cooper; Yifan Dai; Thomas E Starzl Journal: Immunology Date: 2013-09 Impact factor: 7.397
Authors: David K C Cooper; Hidetaka Hara; Mohamed Ezzelarab; Rita Bottino; Massimo Trucco; Carol Phelps; David Ayares; Yifan Dai Journal: J Biomed Res Date: 2013-06-12